1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/61656
Full metadata record
DC FieldValueLanguage
dc.creatorFlavia Amaral Duartept_BR
dc.creatorCarlos Gil Ferreirapt_BR
dc.creatorRodrigo Dienstmannpt_BR
dc.creatorBruno L. Ferraript_BR
dc.creatorMatheus Costa e Silvapt_BR
dc.creatorPedro Nazareth A . Juniorpt_BR
dc.creatorPaulo Guilherme de Oliveira Sallespt_BR
dc.creatorPaulo Henrique Costa Dinizpt_BR
dc.date.accessioned2023-12-01T21:11:54Z-
dc.date.available2023-12-01T21:11:54Z-
dc.date.issued2022-
dc.citation.volume10pt_BR
dc.citation.issue1pt_BR
dc.identifier.doihttps://doi.org/10.1080/20016689.2022.2077905pt_BR
dc.identifier.issn2001-6689pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/61656-
dc.description.resumoBackground: Precision oncology has a prominent role in nonsquamous non-small cell lung cancer (nsNSCLC) treatment progress; however, its access in a real-world scenario might be limited. Objective: To investigate the time spent in nsNSCLC molecular profile evaluation and its influence on clinical decisions. Methods: nsNSCLC patients who underwent molecular testing in a private referral Brazilian center between November 2015 and February 2020 were identified. The interval from nsNSCLC diagnosis to the characterization of the molecular profile was determined. Other outcomes, focusing on the biomarker tissue journey, were also assessed. Results: In this cohort (n = 78), the median time between the advanced nsNSCLC diagnosis and biomarker characterization was 40.5 days (range, 29.5–68.5). The median interval between the diagnosis and the test request was longer than the interval between the request and the results (respectively 29.0 versus 12.0 days; p < 0.001). At the treatment initiation, 51% (36/71) of the patients who received any systemic therapy did not have their driver mutations panel results available. But on these, 42% (15/36) had a targetable alteration identified later on. Among patients harboring a targetable alteration, only 46% (n = 13/28) received a tyrosine kinase inhibitor (TKI) as first-line therapy. The median time to the TKI initiation was even longer than the median time to all treatment initiation (92.0 versus 40.0 days). Conclusions: Our data show a long median time from advanced nsNSCLC diagnosis and the availability of the biomarker testing in medical practice, which impacted the choice of a non-personalized therapy as the first-line.pt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofJournal of Market Access & Health Policypt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectPrecision medicinept_BR
dc.subjectDrug accesspt_BR
dc.subjectNon-small cell lung cancerpt_BR
dc.subject.otherMedicina de precisãopt_BR
dc.subject.otherAcesso aos serviços de saúdept_BR
dc.subject.otherCarcinoma pulmonar de células não pequenaspt_BR
dc.titleBarriers in precision medicine implementation among advanced nonsquamous cell lung cancer-patients: a real-world evidence scenariopt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.tandfonline.com/doi/full/10.1080/20016689.2022.2077905pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-4647-9788pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-7228-7018pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0001-5997-318Xpt_BR
dc.identifier.orcidhttp://orcid.org/0000-0001-8839-3491pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0003-2016-5593pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
Barriers in precision medicine implementation among advanced nonsquamous cell lung cancer-patients_ a real-world evidence scenario .pdf7.09 MBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.